Prevalence of lifetime depression in a large hemiplegic migraine cohort

Neurology. 2016 Nov 29;87(22):2370-2374. doi: 10.1212/WNL.0000000000003376. Epub 2016 Nov 2.

Abstract

Objective: To determine the prevalence of depression and determinants associated with depression in a large population of hemiplegic migraine (HM) patients.

Methods: We conducted a cross-sectional, validated questionnaire study among 89 well-defined HM patients and 235 headache-free controls. The prevalence of lifetime depression and its relation to migraine characteristics was assessed.

Results: HM patients had increased odds for lifetime depression (odds ratio 3.73, 95% confidence interval 2.18-6.38) compared with controls. Use of acute antimigraine medication was associated with lifetime depression.

Conclusions: Depression is part of the monogenic hemiplegic migraine phenotype. Further studies are needed to elucidate the pathophysiologic role of HM genes in comorbid depression. For now, clinicians should take comorbid depression into consideration when starting prophylactic treatment of HM.

MeSH terms

  • Adult
  • Aged
  • Anxiety / epidemiology
  • Central Nervous System Agents / adverse effects
  • Central Nervous System Agents / therapeutic use
  • Comorbidity
  • Cross-Sectional Studies
  • Depression / epidemiology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Migraine with Aura / drug therapy*
  • Migraine with Aura / epidemiology*
  • Migraine with Aura / psychology
  • Netherlands
  • Odds Ratio
  • Prevalence
  • Psychiatric Status Rating Scales
  • Sex Factors
  • Socioeconomic Factors
  • Surveys and Questionnaires
  • Young Adult

Substances

  • Central Nervous System Agents